ClinicalTrials.gg
RecruitingNCT06810544Updated Oct 21, 2026

Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss

A Phase 1/2 interventional study of TNG456 and abemaciclib in Non Small Cell Lung Cancer, Glioma Glioblastoma Multiforme and Glioma, Malignant, sponsored by Tango Therapeutics, Inc.. Recruiting at 15 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-21.

Sponsored by Tango Therapeutics, Inc. · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started Mar 2025; still recruiting 1 year 7 months later.
Updated Oct 16, 2026Study contact changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
191
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 3,368 studies in Carcinoma, Non-Small-Cell Lung with a site in United States — 519 open to participants now, 894 under way, 142 of them phase 3. Carcinoma, Non-Small-Cell Lung · United States.

Planned enrollment
647th of 2,995
191 · median 56
Started
2025
with 148 others
Phase 1/2
484 of 3,368
117 open now
Primary completion
2027-03
later than 341 of 892 live
Registered
3,135th of 3,368
by date

Among the 3,368 studies in Carcinoma, Non-Small-Cell Lung with a site in United States, this one is the 647th largest by planned enrollment of the 2,995 interventional ones that give a count, is one of 149 that started in 2025, is one of 484 in phase 1/2, reaches primary completion later than 341 of the 892 other live ones, and was the 3,135th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

519 of the 3,368 studies in Carcinoma, Non-Small-Cell Lung with a site in United States are open now. Recruiting first, the newest first:

514 more — sign in →

All 519 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 3,368 studies in Carcinoma, Non-Small-Cell Lung with a site in United States, or all of them as a file.
02

Study summary

This is a first in human study of TNG456 alone and in combination with abemaciclib in patients with advanced or metastatic solid tumors known to have an MTAP loss. The first part of the study is an open-label, dose escalation and the second part is an open label dose expansion in specific solid tumor types with a confirmed MTAP loss. The study drug, TNG456, is a selective PRMT5 inhibitor administered orally. The study is planned to treat up to 191 participants.

Read the detailed description

This is a Phase 1/2 multi-center, open label study in solid tumor patients who have a confirmed MTAP loss in their tumor. The Phase 1 portion is a dose escalation study of oral TNG456 administered as a single agent and in combination with oral abemaciclib in solid tumor patients with confirmed MTAP loss. In the Phase 2 expansion part of the study, 6 arms defined by confirmed tumor types will enroll in parallel at the RP2D(s) of TNG456 and in combination. In both parts of the study participants who tolerate the drug may continue treatment until disease progression.

03

Conditions studied

  • Non Small Cell Lung Cancer
  • Glioma Glioblastoma Multiforme
  • Glioma, Malignant
  • Solid Tumor
  • Non-Small Cell Adenocarcinoma
  • Lung Cancer
  • Brain Tumor

Keywords

  • MTAP
  • PRMT5 inhibitor
  • CDK 4/6
  • abemaciclib
  • Tango
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Has a tumor with a confirmed MTAP loss
  • Is ≥18 years of age at the time of signature of the main study ICF
  • Has had progression or an inadequate response to or is intolerant of the approved standard of care therapy, no standard of care therapy exists, or the investigator has determined that treatment with the standard of care therapy is not appropriate.
  • Is able to swallow tablets
  • Adequate Organ function/reserve per local labs
  • Negative serum pregnancy test result at screening
  • Has an performance status score of 0 to 1
  • Has based on v1.1 or a confirmed glioblastoma (IDH-wildtype) with radiographic evidence of disease progression or recurrence defined by RANO 2.0.
  • Has an ECOG performance score of 0 to 1 or for GBM has a performance status score ≥70.

Exclusion criteria

Exclusion Criteria:

  • A female patient is who is pregnant or breastfeeding
  • Has impaired GI function or disease that may significantly alter the absorption of oral study treatment(s)
  • Has an active infection requiring systemic therapy
  • Has received prior treatment with a PRMT5 inhibitor or a MAT2A inhibitor
  • Patients in the expansion receiving the combination therapy that have received prior treatment with a CDK4/6 inhibitor
  • cardiovascular disease
  • Has a prior or ongoing clinically significant illness may affect the safety of the patient, impair the assessment of study results or compliance with the protocol
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
191 participants (estimated)

Study arms

  • Experimental
    Single Agent and Combination Dose Escalation

    Solid tumor participants with confirmed MTAP loss will receive escalating doses of TNG456 single agent and in combination with abemaciclib to estimate the MTD

    Drug: TNG456 · Drug: abemaciclib

  • Experimental
    NSCLC Single Agent Dose Expansion

    NSCLC (squamous and non squamous) participants with confirmed MTAP loss will receive TNG456 at the identified RP2D(s)

    Drug: TNG456

  • Experimental
    GBM Single Agent Dose Expansion

    GBM participants with confirmed MTAP loss will receive TNG456 at the identified RP2D(s)

    Drug: TNG456

  • Experimental
    Tumor Agnostic Single Agent Dose Expansion

    Patients with specific solid tumor types that have a confirmed MTAP loss will receive TNG456 at the identified RP2D(s)

    Drug: TNG456

  • Experimental
    NSCLC Combination Expansion

    NSCLC (squamous and non-squamous) participants with confirmed MTAP loss will receive TNG456 at the identified RP2D(s) with abemaciclib

    Drug: TNG456 · Drug: abemaciclib

  • Experimental
    GBM Combination Expansion

    GBM participants with confirmed MTAP loss will receive TNG456 at the identified RP2D(s) with abemaciclib

    Drug: TNG456 · Drug: abemaciclib

  • Experimental
    Tumor Agnostic Combination Expansion

    Participants with specific tumor types with confirmed MTAP loss will receive TNG456 at the identified RP2D(s) with abemaciclib

    Drug: TNG456 · Drug: abemaciclib

Interventions

  • DrugTNG456

    A selective PRMT5 inhibitor

  • A kinase inhibitor

    Also known as: Verzenio

06

What researchers measure

Primary outcomes

  1. Phase 1 Maximum Tolerated Dose

    To determine the MTD, recommended dose(s) (RD), and dosing schedule of TNG456 monotherapy and in combination with abemaciclib

    Time frame: 21 days

  2. Phase 2 Anti-neoplastic Activity Single Agent

    To assess the antitumor activity of TNG456 in patients with advanced or metastatic solid tumors with MTAP loss by RECIST or modified RANO criteria

    Time frame: 18 weeks

  3. Phase 2 Anti-neoplastic Activity Combination Treatment

    To assess the antitumor activity of TNG456 in combination with abemaciclib in patients with advanced or metastatic tumors with MTAP loss by RECIST or modified RANO criteria

    Time frame: 18 weeks

Secondary outcomes

  1. Phase 1 Anti-neoplastic Activity Single Agent

    To assess preliminary evidence of antitumor activity of TNG456 in patients with advanced solid tumors with MTAP loss by RECIST or modified RANO criteria

    Time frame: 18 weeks

  2. Phase 1 and 2 Adverse Event Profile

    To describe the safety and tolerability profile of TNG456 as a monotherapy and in combination with abemaciclib

    Time frame: 21 days

  3. Phase 1 and 2 Concentration versus Time Curve

    Measure the area under the plasma concentration versus time curve (AUC)

    Time frame: 16 days

  4. Phase 1 and 2 Time to Achieve Maximal Plasma Concentration

    Measure the time to achieve maximal plasma concentration (Tmax)

    Time frame: 16 days

  5. Phase 1 and 2 Maximum Observed Plasma Concentration

    Measure the maximum observed plasma concentration (Cmax)

    Time frame: 16 days

07

Study locations

15 of 15 sites recruiting
  • Mayo Clinic Scottsdale
    Scottsdale, Arizona 85259-5452, United States
    Recruiting
    • Mitesh Borad, MD · Principal investigator
  • University of California, Irvine
    Irvine, California 92686, United States
    Recruiting
    • Cathleen Park, MD · Principal investigator
  • University of California Los Angeles
    Los Angeles, California 90995, United States
    Recruiting
    • Timothy Cloughesy, MD · Principal investigator
  • University of California at San Francisco
    San Francisco, California 94143-2202, United States
    Recruiting
    • Nicolas Butowski, MD · Principal investigator
  • Sibley Memorial Hospital
    Washington D.C., District of Columbia 20016, United States
    Recruiting
    • Solmaz Sahebjam, MD · Principal investigator
  • Mayo Clinic Jacksonville
    Jacksonville, Florida 32224, United States
    Recruiting
    • Hani Babiker, MD · Principal investigator
  • Northwestern Memorial Hospital
    Chicago, Illinois 60611-2908, United States
    Recruiting
    • Ditte Primdahl, MD · Principal investigator
  • Dana Farber Cancer Institute
    Boston, Massachusetts 02215, United States
    Recruiting
    • Jia Luo, MD · Principal investigator
  • Mayo Clinic Cancer Center
    Rochester, Minnesota 55905-0001, United States
    Recruiting
    • Kaushal Parikh, MD · Principal investigator
  • NYU Langone Health
    New York, New York 10016, United States
    Recruiting
    • Salman Punekar, MD · Principal investigator
  • Memorial Sloan Kettering Cancer Center
    New York, New York 11065, United States
    Recruiting
    • Lauren Schaff, MD · Principal investigator
  • Ohio State University Comprehensive Cancer Center
    Columbus, Ohio 43210, United States
    Recruiting
    • Dwight Owen, MD · Principal investigator
  • MD Anderson Cancer Center
    Houston, Texas 77030, United States
    Recruiting
    • Jordi Rodon, MD · Principal investigator
  • University of Utah, Huntsman Cancer Institute
    Salt Lake City, Utah 84112-5500, United States
    Recruiting
    • Howard Coleman, MD · Principal investigator
  • NEXT Virginia
    Fairfax, Virginia 22031, United States
    Recruiting
    • Alexander Spira, MD, PhD · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2025 (actual). Primary completion is estimated for Mar 2027, 24 months after the start.

Of 309 industry-sponsored phase 1/2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 77. This study's planned 24 months is below that.

Counting every sponsor, half of 432 studies reached it within 63 months; a quarter within 42 and three quarters within 80.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 24, 2025
First posted
Feb 5, 2025
StartActual
Mar 24, 2025
Primary completionEst.
Mar 31, 2027
CompletionEst.
Sep 30, 2027
Last update
Oct 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Contact
Study contact changed: c•••@tangotx.com · •••4899→c•••@tangotx.com · •••4899. See the current contact
Oct 16, 2026
Show all 1 update
  1. Oct 16, 2026
    Contact Study contact changed: c•••@tangotx.com · •••4899→c•••@tangotx.com · •••4899. See the current contact

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06810544
Lead sponsor
Tango Therapeutics, Inc.
Responsible party
Sponsor
First posted
Feb 5, 2025
Start date
Mar 24, 2025
Primary completion
Mar 31, 2027 (estimated)
Completion
Sep 30, 2027 (estimated)
Last update
Oct 21, 2026

Study contacts

Adam Crystal, MD, PhD
Contact
clinicaltrials@tangotx.com
(857) 320-4899
Adam Crystal, MD, PhD
study director · Tango Therapeutics, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion